Odyssey Health, Inc. Provides Recap on Concussion Drug Development
06 oct. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program
30 sept. 2022 18h28 HE
|
Odyssey Health, Inc
Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the “Company” “Odyssey”) a company focused on developing a unique...
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
28 sept. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
New Study Reveals Effective Treatment for Children Suffering From Persistent Post-Concussion Syndrome
23 sept. 2022 13h51 HE
|
Aviv Clinics
ORLANDO, Fla., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Today, Aviv Clinics highlights a new study published in Scientific Reports showing an effective treatment to heal damaged brain tissue and relieve...
electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
21 sept. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark...
The Carrick Institute to Host 1-Day Concussion Bootcamp Workshop at 37th World Congress of Sports Medicine
20 sept. 2022 14h00 HE
|
Carrick Institute
GUADALAJARA, Mexico, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The Carrick Institute, world leader in clinical neuroscience education, proudly announced today that they will be delivering a 1-day...
Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals
20 sept. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine company, today announced its plans to hold its fiscal...
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II
13 sept. 2022 08h00 HE
|
Odyssey Health, Inc
Las Vegas, NV, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products,...
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder
07 sept. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed...
electroCore to Participate at Upcoming Investor Conferences
06 sept. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer,...